Name: Gain Therapeutics, Inc. (GANX) Financial Statements
Creator: FinSpry

Gain Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Gain Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.06	0.13	0.13	0.00
Cost of Revenue	10.65	11.38	8.24	7.16	2.26
Gross Profit	-10.65	-11.32	-8.11	-7.03	-2.26
Operating Expenses
Research & Development	10.79	11.52	8.38	7.16	0.00
Selling, General & Administrative	9.71	10.93	9.68	6.84	1.25
Operating Expenses	9.71	10.93	9.68	6.81	1.22
Operating Income	-20.36	-22.26	-17.79	-13.84	-3.48
Other Income/Expense
Interest Income	0.37	0.50	0.39	0.02	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	0.12	-0.43	-0.10	-0.94	0.00
Income
Income Before Tax	-19.87	-22.19	-17.50	-13.89	-3.57
Income Tax Expense	0.54	0.08	0.09	0.00	0.01
Net Income	-20.41	-22.27	-17.59	-13.89	-3.58
Net Income - Continuous Operations	-20.41	-22.27	-17.59	-13.89	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-20.32	-22.22	-17.76	-13.82	-3.47
EBIT	-20.36	-22.26	-17.79	-13.84	-3.48
Depreciation & Amortization	0.04	0.04	0.03	0.02	0.01
Earnings Per Share
Basic EPS	-1.00	-2.00	-1.00	-1.00	-1.00
Diluted EPS	-1.00	-2.00	-1.00	-1.00	-1.00
Basic Shares Outstanding	22.88	13.01	11.88	10.17	2.68
Diluted Shares Outstanding	22.88	13.01	11.88	10.17	2.68